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Purpose:  Recent  evidence  suggests  that  neuroglial  dysfunction  and  degeneration  contributes  to  the  etiology  and
progression of diabetic retinopathy. Advanced lipoxidation end products (ALEs) have been implicated in the pathology
of various diseases, including diabetes and several neurodegenerative disorders. The purpose of the present study was to
investigate the possible link between the accumulation of ALEs and neuroretinal changes in diabetic retinopathy.
Methods:  Retinal  sections  obtained  from  diabetic  rats  and  age-matched  controls  were  processed  for
immunohistochemistry using antibodies against several well defined ALEs. In vitro experiments were also performed
using a human Müller (Moorfields/Institute of Ophthalmology-Müller 1 [MIO-M1]) glia cell line. Western blot analysis
was used to measure the accumulation of the acrolein-derived ALE adduct Nε-(3-formyl-3,4-dehydropiperidino)lysine
(FDP-lysine)  in  Müller  cells  preincubated  with  FDP-lysine-modified  human  serum  albumin  (FDP-lysine-HSA).
Responses of Müller cells to FDP-lysine accumulation were investigated by analyzing changes in the protein expression
of heme oxygenase-1 (HO-1), glial fibrillary acidic protein (GFAP), and the inwardly rectifying potassium channel Kir4.1.
In addition, mRNA expression levels of vascular endothelial growth factor (VEGF), interleukin-6 (IL-6), and tumor
necrosis factor-α (TNFα) were determined by reverse transcriptase PCR (RT–PCR). Apoptotic cell death was evaluated
by fluorescence-activated cell sorting (FACS) analysis after staining with fluorescein isothiocyanate (FITC)-labeled
annexin V and propidium iodide.
Results: No significant differences in the levels of malondialdehyde-, 4-hydroxy-2-nonenal-, and 4-hydroxyhexenal-
derived ALEs were evident between control and diabetic retinas after 4 months of diabetes. By contrast, FDP-lysine
immunoreactivity was markedly increased in the Müller glia of diabetic rats. Time-course studies revealed that FDP-lysine
initially accumulated within Müller glial end feet after only a few months of diabetes and thereafter spread distally
throughout their inner radial processes. Exposure of human Müller glia to FDP-lysine-HSA led to a concentration-
dependent accumulation of FDP-lysine-modified proteins across a broad molecular mass range. FDP-lysine accumulation
was associated with the induction of HO-1, no change in GFAP, a decrease in protein levels of the potassium channel
subunit Kir4.1, and upregulation of transcripts for VEGF, IL-6, and TNF-α. Incubation of Müller glia with FDP-lysine-
HSA also caused apoptosis at high concentrations.
Conclusions: Collectively, these data strongly suggest that FDP-lysine accumulation could be a major factor contributing
to the Müller glial abnormalities occurring in the early stages of diabetic retinopathy.
Diabetic retinopathy is a major cause of vision loss and
blindness in people of working age in developed countries
[1]. The retinal vasculature is central to the development of
diabetic retinopathy, but there is accumulating evidence that
neuroretinal function is also compromised during this disease,
often before overt vessel changes [2,3]. For example, deficits
in  visual  functioning,  such  as  loss  of  color  vision  [4,5],
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contrast  sensitivity  [6],  and  abnormalities  in  the
electroretinogram  [7],  have  been  documented  in  patients
shortly after the diagnosis of diabetes and before the detection
of  clinically  evident  vascular  retinopathy.  Early  neuronal
changes are also apparent in the retinas of experimental rodent
models  of  diabetes,  including  neurophysiological  defects
similar to those described in human diabetes [8]. Because
neuroretinal changes occur at an early stage of the disease
process, it has been proposed that they may play a causative
or contributory role in the initiation and progression of the
vascular pathology associated with diabetic retinopathy [2,3,
9].
Müller cells are the principal glia of the retina. They span
the  entire  thickness  of  the  retina  from  the  inner  limiting
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2524membrane  to  the  photoreceptor  layer,  and  their  processes
make contact with most neural cells [10]. They also form end
feet on both large vessels and capillaries in the inner and outer
retinal vessel beds [11]. Müller glia are vital for maintaining
normal  neuronal  and  vascular  function  in  the  retina.  In
addition to their mechanical role in stabilizing the retinal
architecture, Müller glia are involved in regulating retinal
glucose  metabolism,  modulating  the  ionic  and  molecular
composition of the retinal microenvironment, altering blood
flow to match the local metabolic needs of the retina, and
contributing to the maintenance of the inner blood–retinal
barrier  [12].  Given  their  importance  in  preserving
neurovascular function in the retina, there is a strong rationale
for exploring Müller glia dysfunction within the context of
diabetic retinopathy.
Several studies over the past two decades have provided
evidence that Müller glia are adversely affected early in the
course  of  diabetes.  Müller  glia  in  both  human  and
experimental  diabetes  acquire  a  “reactive”  phenotype
characterized by cellular hyperplasia [13] and upregulation of
glial  fibrillary  acidic  protein  (GFAP)  [13-15].  In  diabetic
animals, these gliotic changes are accompanied by several
dysfunctional  responses,  including  alterations  in  their
capacity  to  regulate  potassium  and  glutamate  in  the
extracellular  space  [14,16,17],  accumulation  of  γ-
aminobutyric  acid  [18],  upregulation  of  pro-inflammatory
cytokines  [19],  and  increased  expression  of  angiogenic
growth factors, such as vascular endothelial growth factor
(VEGF)  [20]  and  insulin-like  growth  factor  (IGF)-1  [21].
Diabetes has also been reported to accelerate death of Müller
glia through activation of apoptotic signaling cascades [22].
Although much progress has been made toward characterizing
the nature of Müller glial abnormalities in the diabetic retina,
the specific mechanisms involved remain poorly understood.
Oxidative  stress  is  strongly  implicated  in  the
development of diabetic retinopathy [23]. A possible pathway
through which oxidative stress may contribute to retinal cell
dysfunction and degenerative changes during diabetes is by
promoting  the  formation  of  advanced  lipoxidation  end
products  (ALEs)  [24,25].  ALEs  form  through  the
lipoperoxidative  production  of  reactive  aldehyde  species,
such  as  malondialdehyde  (MDA),  4-hydroxy-2-nonenal
(HNE), 4-hydroxyhexenal (HHE), and acrolein (ACR), which
readily form stable adducts on proteins [26]. These adducts
include  Nε-(2-propenal)lysine  and  dihydropyridine-type
adducts (DHP-lysine; MDA-derived), hemiacetal and pyrrole
adducts (HNE- and HHE-derived), and β-substituted propanal
adducts  and  Nε-(3-formyl-3,4-dehydropiperidino)lysine
(FDP-lysine; ACR-derived) [26]. Such ALEs may induce a
variety of cytopathological effects, including cross-linking of
cell-surface proteins, inactivation of enzymes, and stimulation
of pro-inflammatory and pro-apoptotic signaling pathways
[27,28], and they have been identified as pathogenic agents in
cardiovascular  and  neurodegenerative  disorders  [29].  The
pathogenic significance of ALEs in diabetic retinopathy is less
well established, although we have recently demonstrated that
hemoglobin levels of the ACR-derived ALE, FDP-lysine, are
associated with the severity of retinopathy in type 1 and type
2 diabetic patients [25].
In an effort to advance our understanding of the possible
contribution of ALE formation in the pathogenesis of diabetic
retinopathy,  we  have  performed  immunohistochemistry
studies  using  a  panel  of  specific  antibodies  to  assess  the
accumulation  of  DHP-lysine,  4-HNE-histidine,  4-HHE-
histidine,  and  FDP-lysine  in  the  retina  during  early
experimental  diabetes.  Here  we  report  that  FDP-lysine
selectively and progressively accumulates in retinal Müller
glia in experimental diabetes. Complementary in vitro studies
demonstrate the effects of FDP-lysine-modified protein on the
function and viability of retinal Müller glia. The data indicate
that  FDP-lysine  accumulation  may  play  a  key  role  in
mediating  Müller  glia  dysfunction  during  diabetic
retinopathy.
METHODS
Diabetic studies:
Experimental  animals—Male  Sprague-Dawley  rats
(150–200 g; Harlan Laboratories, Horst, Netherlands) were
TABLE 1. WEIGHT AND GLYCOSYLATED HEMOGLOBIN LEVELS OF THE EXPERIMENTAL ANIMALS.
Group Months of diabetes n Bodyweight (g) GHb (%)
Control na 9 337±3.9 5.3±0.1
STZ 1 9 238±8.7 20.8±0.8
Control na 10 419±6.8 6.4±0.3
STZ 2 6 298±15.8 19.5±1.3
Control na 10 438±8.2 6.4±0.2
STZ 3 10 286±12.5 20±1
Control na 10 431±9.4 6.4±0.1
STZ 4 9 287±9.4 18.9±1.2
Abbreviations: STZ represents streptozotocin-induced diabetic rats; n represents number of rats per experimental group.
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2525rendered  diabetic  by  a  single  intraperitoneal  injection  of
streptozotocin (STZ; 65mg/kg; Sigma, Poole, UK) dissolved
in 20 mM/l fresh citrate buffer, pH 4.6. After 1 week, the rats
were weighed and those with plasma glucose concentrations
>15 mM/l (Ascensia Esprit 2 blood glucose meter, Bayer
Diagnostics Europe Ltd, Dublin, Ireland) were included in the
study as diabetic. Nondiabetic animals were sham injected
with  citrate  buffer  only.  Animals  were  killed  by  CO2
inhalation followed by cervical dislocation 1, 2, 3, or 4 months
post  injection  of  STZ  or  citrate  buffer.  Animals  were
reweighed, and blood was collected from the tail vein into
heparinized tubes for measurement of percentage levels of
glycosylated  hemoglobin  (GHb;  Helena  Biosciences,
Gateshead, UK) immediately before sacrifice. The number of
animals used at each time point in the study is summarized in
Table 1. All procedures with animals were approved by The
Queen’s University of Belfast Animal Ethics Committee and
were performed in accordance with the Guide for the Care and
Use of Laboratory Animals published by the US National
Institutes  of  Health  (NIH  Publication  No.  85–23,  revised
1996) and the UK Animals (Scientific Procedures) Act, 1986.
Antibodies and advanced lipoxidation end product-
modified  proteins—Mouse  monoclonal  anti-FDP-lysine
(mAb5F6)  and  anti-4-HNE  (mAbR310)  antibodies  were
prepared as previously described [30,31]. For the detection of
HHE- and MDA-modified proteins, monoclonal anti-4-HHE
(clone HHE53) and anti-MDA (clone 1F83) antibodies were
purchased from the Japan Institute for the Control of Aging
(Shizuoka,  Japan).  FDP-lysine-,  4-HNE-,  and  4-HHE-
modified human serum albumin (HSA) were prepared by
reacting 10 mg/ml HSA (Sigma, Poole, UK) with 10 mM ACR
(Sigma), 4-HNE or 4-HHE (Enzo Life Sciences [UK] Ltd,
Exeter, UK) in 50 mM sodium phosphate buffer (PBS; 14 mM
NaH2PO4, 36 mM Na2HPO4, pH 7.2) at 37 °C for 24 h in the
dark. Unbound aldehyde was removed by 72 h dialysis at 4 °C
against 50 mM PBS with 10 kDa cut-off tubing (Thermo
Fisher  Scientific,  Loughborough,  UK).  The  resulting
aldehyde-modified HSA samples were then filter sterilized
with a 0.2-μm filter (Millipore, Watford, UK) before use.
MDA-modified  BSA  (BSA)  was  purchased  from  Abcam
(Cambridge,  UK).  Polyclonal  antibodies  against  heme
oxygenase 1 (HO-1), GFAP, and Kir4.1 were obtained from
Abcam,  Dako  (Ely,  UK),  and  Caltag-Medsystems  Ltd
(Buckingham, UK), respectively.
Dot  blot  analysis  of  antibody  specificity—Dot  blot
analysis was used to test the specificity of the monoclonal anti-
ALE antibodies. Polyvinylidene fluoride (PVDF) membranes
(Westran®, Roche Diagnostics Limited, Burgess Hill, West
Sussex, UK) were dipped in 100% methanol, rinsed with
water, then soaked in Tris-buffered saline with Tween-20
(TTBS; containing 100 mM Tris-HCl, 150 mM NaCl, 0.1%
Tween-20 [v/v], pH 7.5) for 5 min. Five microliters of each
ALE-modified protein, containing 12 μg protein, were then
spotted onto the PVDF membrane and allowed to slowly air
dry  overnight.  Membranes  were  washed,  and  nonspecific
protein-binding sites blocked with 5% nonfat dry milk for 2 h
at  21  °C.  Membranes  were  washed  again  and  incubated
overnight at 4 °C with primary antibody diluted 1:100 (anti-4-
HNE-, anti-4-HHE, or anti-MDA antibodies) or 1:1,000 (anti-
FDP-lysine antibody) with TTBS containing 2% nonfat dry
milk. After extensive washing with TTBS, membranes were
exposed for 1 h at 21 °C to peroxidase-labeled goat antimouse
immunoglobulin  (IgG)  antibody  (diluted  1:200;  Sigma).
Membranes were washed again and the blots developed using
the  Immobilon  Western  chemiluminescent  horseradish
peroxidase  substrate  (Millipore)  and  detected  by  an
AutochemiTM system (UltraViolet Products Ltd, Cambridge,
UK).
Immunohistochemistry—Eyes  were  enucleated,
hemisected  along  the  ora  serrata,  and  the  vitreous  humor
removed.  Eyecups  were  immersion  fixed  in  4%  (w/v)
paraformaldehyde for 30 min, washed in PBS, and the retinas
detached.  Fixed  retinas  were  cryoprotected,  embedded  in
Tissue-Tek OCT compound (Sakura Finetek, Torrance, CA),
snap frozen in liquid nitrogen-cooled isopentane, and 12-μm
cryosections prepared.
Cryosections were mounted onto slides, rinsed in PBS,
and  nonspecific  binding  sites  blocked  using  10%  normal
donkey serum and 0.5% Triton X-100 in PBS. The slides were
then rinsed in PBS and incubated with the primary antibody
diluted in 10% normal goat serum, 0.3% Triton X-100, and
0.1% NaN3 for 24 h at 4 °C. Primary antibodies were used at
the following dilutions: anti-4-HNE, anti-4HHE, and anti-
MDA,  1:100;  anti-FDP-lysine  and  anti-GFAP,  1:1,000.
Sections were rinsed thoroughly to remove unbound primary
antibody  and  incubated  in  an  appropriate  fluorescent-
conjugated  secondary  antibody  (Alexa  fluor488  donkey
antimouse IgG or donkey antirabbit IgG; Invitrogen, Paisley,
UK), diluted 1:200 in 10% donkey serum in PBS, for 1 h at
TABLE 2. PRIMER SEQUENCES FOR QUANTITATIVE RT–PCR AND GENBANK ACCESSION NUMBERS.
Gene Forward primer (5′-3′) Reverse primer (5′-3′) Accession number
VEGFA CCCACTGAGGAGTCCAACAT TTTCTTGCGCTTTCGTTTTT NM_001025366.2
IL-6 TACCCCCAGGAGAAGATTCC TTTTCTGCCAGTGCCTCTTT NM_000600.3
TNFα AACCTCCTCTCTGCCATCAA CCAAAGTAGACCTGCCCAGA NM_000594.2
β-actin AGAGCTACGAGCTGCCTGAC AGCACTGTGTTGGCGTACAG NM_001101.3
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2526room  temperature.  Slides  were  mounted  in  Vectashield
antifade (Vector Laboratories, Peterborough, UK) containing
5  μg/ml  propidium  iodide.  Multiple  immunolabeling  was
performed by simultaneous incubation of sections with anti-
FDP-lysine and anti-GFAP, and the sections subsequently
washed and incubated in secondary antibodies Alexa fluor488
donkey antimouse IgG and Alexa fluor568 donkey antirabbit
IgG. For these slides Vectashield in the presence of 1.5 μg/ml
DAPI  nuclear  stain  was  used  as  the  mounting  media.
Appropriate negative and pre-absorption controls were also
performed.
Fluorescence was visualized by using a Nikon TE-2000
C1 confocal system (Nikon Ltd, Kingston upon Thames, UK).
Images were obtained from three areas of the retina: inferior
central (0 to 1 mm below the optic nerve head) and inferior
peripheral and superior peripheral (0 to 2 mm from the inferior
or superior peripheral edge of the retina, respectively) regions.
Measurements  of  immunofluorescence  intensity  were
performed  using  ImageJ  software  (Wayne  Rasband,  NIH,
Bethesda, MD) as previously described [32]. In some sections
it  was  not  possible  to  identify  precisely  the  boundaries
between the inner limiting membrane (ILM) and nerve fiber
layer (NFL) and the NFL and ganglion cell layer (GCL), and
therefore  these  regions  were  combined  for  quantification.
Either the left or the right eye were analyzed for each rat. In
each experimental protocol, a total of nine tissue sections was
imaged  per  retina  (three  sections  from  each  of  the  three
designated areas examined), and mean values were calculated
for use in subsequent statistical analyses.
In  vitro  studies:  MIO-M1  Müller  glia  cells  [33]  were
maintained  in  Dulbecco’s  modified  Eagle’s  medium
supplemented  with  10%  fetal  calf  serum  and  10  mg/ml
primocin. Cells were grown to near confluency, serum starved
for  24  h,  and  then  treated  with  FDP-lysine-HSA  at
concentrations from 0.05 to 0.5 mg/ml for an additional 24 h.
Cells  were  used  from  passages  42  to  55.  All  in  vitro
experiments were performed in triplicate.
Western blot analysis—Western immunoblotting was
performed  as  previously  described  [34].  Briefly,  protein
samples of MIO-M1 cells exposed to FDP-lysine-HSA were
prepared by scraping the cells off the flask in an extraction
buffer solution of PBS containing protease inhibitors (Roche
Diagnostics). Protein concentration was determined using the
BCA protein assay kit (Thermo Fisher Scientific), and 30 μg
Figure  1.  Specificity  of  the  anti-
advanced  lipoxidation  end  product
antibodies.  Representative  dot  blots
showing  the  specificity  of  the  anti-
advanced  lipoxidation  end  product
(ALE)  monoclonal  antibodies  to
aldehyde-modified  proteins.  Anti-Nε-
(3-formyl-3,4-
dehydropiperidino)lysine (FDP-lysine),
anti-malondialdehyde  (MDA)-lysine,
anti-4-hydroxy-2-nonenal  (HNE)–
histidine,  and  anti-4-hydroxyhexenal
(HHE)-histidine monoclonal antibodies
reacted  specifically  with  FDP-lysine
human  serum  albumin  (HSA),  MDA
BSA (BSA), 4-HNE-HSA, and 4-HHE-
HSA, respectively.
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2527of  protein  was  subjected  to  10%  SDS–PAGE.  Western
blotting was performed by incubating the PVDF membrane
with anti-FDP-lysine (1:10,000), anti-HO-1 (1:1,000), anti-
GFAP (1:3,000), or anti-Kir4.1 (1:500) antibodies together
with  rabbit  polyclonal  or  mouse  monoclonal  β-actin
antibodies (1:3,000 and 1:20,000, respectively; Sigma) at 4 °C
overnight. After washing, the membrane was incubated with
appropriate  IRDye  680  and  IRDye  800  goat  secondary
antibodies against mouse or rabbit IgG (Li-COR, Cambridge,
UK)  at  room  temperature  for  30  min.  Membranes  were
imaged with an Odyssey Infrared Imaging System (Li-COR).
Color  images  were  converted  to  grayscale,  background
subtracted,  and  the  integrated  density  of  protein  bands
determined using ImageJ. Data were normalized to β-actin-
loading controls and presented as fold changes compared with
untreated cells.
RNA  isolation  and  RT–PCR—MIO-M1  RNA  was
extracted  using  Tri-Reagent  (Sigma),  and  quality  was
confirmed  by  measurement  of  the  A260:A280  ratio.  The
Improm-II reverse transcription system (ImProm II, Promega,
MSC, Dublin, Ireland) was used to synthesize cDNA, with
1  μg  of  MIO-M1  RNA  and  random  hexamer  primers,
Figure 2. Immunohistochemical staining for 4-hydroxy-2-nonenal (HNE), 4-hydroxyhexenal (HHE), and malondialdehyde (MDA) modified
proteins (green fluorescence) in transverse cryosections of retina from nondiabetic (NonDb) and diabetic (Db) rats of 4 months disease duration.
Propidium iodide was used to counterstain cell nuclei (red fluorescence). In nondiabetic retina, weak diffuse immunoreactivity for each of
these advanced lipoxidation end products (ALEs) was detected, although stronger cytoplasmic staining for 4-HHE and MDA-modified proteins
was observed for a small number of cells located within the ganglion cell layer (GCL) and at the outer border of the inner nuclear layer (INL;
arrows). Immunolabelled sections from diabetic rats appeared similar to those of nondiabetic rats. When quantified, no significant differences
in the intensity of staining for 4-HNE, 4-HHE, and MDA modified proteins was apparent between retinas from the nondiabetic and diabetic
animals.
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2528according to the manufacturer's instructions. Real-time PCR
analysis was performed for quantitative analysis of mRNA
expression as previously described [35]. Sequence-specific
primers were designed using the program Primer3 to amplify
VEGF, interleukin-6 (IL-6), tumor necrosis factor-α (TNF-
α), and β-actin (for primer sequence data, see Table 2). Results
were normalized to β-actin, and expression was compared to
Figure  3.  Nε-(3-formyl-3,4-
dehydropiperidino)lysine  (FDP-lysine)
immunoreactivity (green fluorescence)
in  vertical  sections  of  retina  from
nondiabetic (NonDb) and diabetic (Db)
rats of 4 months disease duration. Nuclei
were  counterstained  with  propidium
iodide (red fluorescence). A: Low and
high  magnification  images  of  FDP-
lysine immunoreactivity in the normal
rat retina. Strong immunolabelling was
detected in the retinal ganglion cell layer
(GCL) and nuclei in the inner nuclear
layer  (INL).  B:  Low  and  high  power
confocal  micrographs  of  FDP-lysine
immunoreactivity in diabetic rat retina.
Prominent immunolabelling appeared at
the ILM and in radial processes in the
inner retina (arrows). C: Summary data
showing  that  diabetes  caused  a
statistically significant increase in FDP-
lysine  immunolabelling  limited  the
innermost retinal layers.
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2529normal levels in untreated cells using the delta Ct method
[35].
Apoptosis analysis—Apoptosis was analyzed by flow
cytometry, using annexin V and propidium iodide according
to  the  manufacturer’s  instructions  (Annexin  V-FITC
Apoptosis Detection Kit I; BD Biosciences, Oxford, UK).
Briefly, after treatment cells were trypsinized, washed in cold
PBS,  and  resuspended  in  assay  buffer.  Annexin  V  and
propidium iodide solution were added to the cell preparations
and incubated for 15 min in the dark at room temperature.
Binding buffer was then added to each tube, and the samples
were analyzed using a FACS Calibur flow cytometer (BD
Biosciences)  and  FlowJo  software  V7.5.5  (Tree  Star,
Ashland, OR). For each sample, 20,000 events were acquired.
Respective negative controls were used to determine accurate
settings for data analysis.
Data analysis and statistical calculations: Data are presented
as means±SEM. Statistical analyses were performed using
Prism V4.02 (Graphpad Software, San Diego, CA). Western
blot and qRT–PCR data were analyzed before conversion to
fold-change  units,  while  data  on  apoptosis  were  arcsine
transformed  before  analysis.  Normal  distribution  was
assessed by the D’Agostino and Pearson omnibus normality
test.  For  immunohistochemical  and  apoptosis  data,
differences  among  groups  were  analyzed  with  a  two-way
ANOVA followed by Bonferroni’s post hoc test. All other
data  were  analyzed  by  one-way  ANOVA  followed  by
Newman–Keuls  multiple  comparison.  In  all  figures,
significant differences are represented with a single asterisk
when the p value is less than 0.05, with two asterisks when
the p value is less than 0.01, and three asterisks when the p
value is less than 0.001.
RESULTS
Animals: The general condition of the STZ-diabetic rats was
assessed by measuring bodyweights and GHb (Table 1). All
STZ-diabetic animals gained weight during the course of the
study, but their growth was significantly reduced as compared
to that observed in control animals (p<0.001 for all time points
after diabetes induction). Nondiabetic rats had normal mean
GHb values ranging between 5.3% and 6.4%, while in diabetic
rats the mean GHb levels were threefold to fourfold higher
(p<0.001).
Epitope  specificity  of  anti-ALE  antibodies:  Prior  to
immunolocalization studies, the specificities of the anti-ALE
antibodies  were  tested  by  western  dot  blot  analysis.  The
reactivity of the antibodies was examined against FDP-lysine-
HSA, MDA-BSA, 4-HNE-HSA, and 4-HHE-HSA. Each of
the  antibodies  reacted  strongly  with  its  corresponding
antigenic  protein  with  no  cross-reactivity  (Figure  1).  No
immunoreactivity  was  detected  with  the  relevant  carrier
proteins HSA or BSA.
Selective  accumulation  of  FDP-lysine  adducts  in  retinal
Müller glia during diabetes: We began by examining the
Figure 4. Co-localization of Nε-(3-formyl-3,4-dehydropiperidino)lysine (FDP-lysine) and glial fibrillary acidic protein (GFAP) in the diabetic
retina. Retinal sections from nondiabetic (NonDb) and diabetic (Db) rats were labeled with 4',6-diamidino-2-phenylindole (DAPI) nuclear
stain (A and E), GFAP (B and F), and FDP-lysine (C and G). In the nondiabetic retina, GFAP immunoreactivity was selectively localized to
astrocytes at the inner retinal surface. In diabetes, Müller cells acquired prominent GFAP immunoreactivity within their end feet at the
vitreoretinal border and throughout their radial processes spanning from the inner to the outer limiting membranes. D and H: In merged images,
FDP-lysine was found to co-localize strongly with GFAP in the retina of diabetic but not nondiabetic rats. The scale bars indicate 50 μm.
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2530distribution  and  accumulation  of  ALE  adducts  in  retinal
tissues  from  diabetic  rats  of  4  months  disease  duration.
Previous work has reported that only very low levels of 4-
HNE-, 4-HHE-, and MDA-modified proteins are detectable
in  retinal  tissues  from  normal  control  animals  [36,37].
Similarly,  we  found  sparse  immunoreactivity  for  these
adducts  in  the  retinas  of  nondiabetic  rats  (Figure  2).  No
differences in the intensity or distribution of the staining for
4-HNE-, 4-HHE, and MDA-modified proteins were evident
in retinas from diabetic rats (Figure 2; p>0.05 for all cell
layers).  In  the  nondiabetic  retina,  the  anti-FDP-lysine
antibody strongly stained a population of cells in the GCL and
nuclei in the inner nuclear layer (INL, Figure 3A), and diffuse
immunoreactivity was present across the other layers of the
retina. In diabetic retina there was a marked increase in FDP-
lysine  immunoreactivity  in  the  inner  layers  of  the  retina
(Figure 3B,C). In particular, prominent immunolabelling was
evident at the ILM and within radial processes extending from
the ILM to the INL. This staining pattern corresponded to
Müller glia with end feet at the ILM and distal processes
traversing  the  inner  plexiform  layer  (IPL)  [10].  Primary
antibody  omission  and  pre-absorption  controls  were
completely negative for all ALEs investigated (mean pixel
intensities were <1 after background subtraction).
Figure 5. Spatiotemporal characteristics of Nε-(3-formyl-3,4-dehydropiperidino)lysine (FDP-lysine) accumulation in diabetic Müller cells.
A and B: Representative confocal images of FDP-lysine immunoreactivity in retinal sections from non-diabetic rats 1 and 4 months post
injection of citrate buffer. C-F: Immunohistochemisty for FDP-lysine in retinal sections from STZ-diabetic rats 1, 2, 3, and 4 months after
the induction of diabetes. The intensity of FDP-lysine staining initially increased in the end feet of Müller cells at the ILM after 2 months of
diabetes (D, arrows) and subsequently spread throughout their inner processes extending from the ILM to the INL (E, F, arrows). G: Summary
data revealed that FDP-lysine immunoreactivity was significantly increased in diabetic retina in regions of the ILM–GCL and IPL, 2 and 3
months following the onset of diabetes, respectively. There was no significant difference in FDP-lysine in the outer retina at any time point
between the nondiabetic and diabetic groups. The scale bars refer to 50 μm.
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2531To confirm that FDP-lysine selectively accumulates in
retinal  Müller  glia  during  diabetes,  double-labeling
experiments were performed using anti-FDP-lysine and anti-
GFAP antibodies (Figure 4). Previous studies have shown that
after  4  months  of  STZ-induced  diabetes,  retinal  GFAP  is
upregulated in Müller glia and relatively downregulated in
astrocytes [38]. In nondiabetic rat retinas, GFAP expression
was limited to cells along the inner margin of the retina with
a morphology and distribution characteristic of astrocytes. In
diabetic retina, intense GFAP immunoreactivity was detected
in both the Müller glial end feet and along radial processes
extending to the outer limiting membrane. FDP-lysine co-
localized with GFAP in the diabetic retina, suggesting that the
accumulation of this adduct was largely restricted to Müller
glia.
Spatiotemporal  pattern  of  FDP-lysine  accumulation  in
diabetic Müller cells: The spatiotemporal pattern of FDP-
lysine  accumulation  in  Müller  glia  during  experimental
diabetes was investigated over a period of 1 to 4 months
disease duration. As shown in Figure 5, no significant changes
in FDP-lysine immunoreactivity were evident over the first
month  of  diabetes.  At  2  months,  FDP-lysine  levels  were
strongly elevated at the ILM, but no detectable increase was
apparent in the IPL. By 3 months of diabetes, strong staining
for FDP-lysine was not only visible along the ILM, but also
in the NFL and GCL. In addition, a small but significant
increase in FDP-lysine immunoreactivity was seen in the IPL
due to faint staining of radial processes. As described earlier,
after 4 months of diabetes, strong positive immunolabelling
for FDP-lysine was seen in both the Müller glial end feet at
the ILM and their adherent inner processes. No discernible
changes in FDP-lysine immunoreactivity were seen in the
nondiabetic rat retina over the 4-month time frame. Overall,
these results strongly suggest that the accumulation of FDP-
lysine-modified proteins in Müller glia is progressive as a
function of diabetes duration, with adducts initially localizing
to the end feet at the vitreoretinal border and then spreading
distally to processes at the outer retina.
FDP-lysine accumulation mediates Müller glia dysfunction
and death in vitro: To gain an insight into the pathogenic
potential of FDP-lysine in Muller glia, we adopted an in vitro
approach. Western blotting for FDP-lysine adducts from both
control  and  FDP-lysine-HSA  exposed  MIO-M1  cells
demonstrated  a  concentration-dependent  increase  in  the
abundance  of  FDP-lysine  protein  adducts  over  a  broad
molecular mass range (Figure 6). It was notable that a step
change  in  FDP-lysine  immunoreactivity  occurred  at  the
highest concentration of FDP-lysine-HSA studied (0.5 mg/
ml). Cells incubated with FDP-lysine-HSA showed a ~68 kDa
band (consistent with FDP-lysine-HSA), which was absent in
lysates from control cells (arrow, Figure 6A). In addition,
several higher molecular weight bands were evident in cells
exposed to concentrations of FDP-lysine-HSA ≥0.2 mg/ml.
These data correspond with previous work showing that FDP-
lysine  is  not  a  stable  end  product  but  acts  as  a  reactive
intermediate  capable  of  mediating  protein–protein  cross-
linking reactions [39].
Figure 6. In vitro model of Nε-(3-formyl-3,4-dehydropiperidino)lysine (FDP-lysine) accumulation in Müller cells. A: Representative western
blot image showing the abundance of FDP-lysine adducts in human Müller (MIO-M1) cells under control conditions and following treatment
with  increasing  concentrations  of  FDP-lysine  human  serum  albumin  (HSA).  MIO-M1  cells  exposed  to  FDP-lysine  HSA  exhibited  a
concentration-dependent increase in FDP-lysine immunoreactivity across a broad molecular mass range. The arrow indicates the expected
size of monomeric FDP-lysine-HSA. B: Mean data showing the fold change in FDP-lysine levels for each treatment group relative to untreated
cells.
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2532Diabetes has been demonstrated to induce Müller cell
oxidative stress, as indicated by an increase in the protein
expression of the antioxidant enzyme HO-1 [40]. In addition
to being generated through oxidative reactions, it has been
proposed that FDP-lysine adducts could give rise to oxidative
stress  via  depletion  of  glutathione  within  the  cell  [39].
Treatment of MIO-M1 cells with FDP-lysine-HSA stimulated
a concentration-dependent increase in HO-1 protein levels
(Figure 7A,D). In western blots of control cell extracts, GFAP
appeared  as  multimeric  bands  at  38,  42,  43,  and  50  kDa
(Figure 7B,E), and no significant differences were observed
in these bands following FDP-lysine-HSA exposure. Another
important alteration that occurs in diabetic Müller cells is a
disruption in their ability to buffer extracellular K+ levels in
the retina [12]. The primary K+ conductance in Müller cells is
mediated by the inwardly rectifying potassium channel Kir4.1
[12], and there was an appreciable downregulation of Kir4.1
protein  levels  in  MIO-M1  cells  treated  with  high
concentrations  of  FDP-lysine-HSA  (≥0.4  mg/ml;  Figure
7C,F).
FDP-lysine-HSA  exposure  altered  mRNA  expression
levels of angiogenic and inflammatory factors known to be
elevated  in  the  vitreous  and  retina  during  diabetes.  FDP-
lysine-HSA  led  to  a  concentration-dependent  increase  in
VEGF transcript levels across the full range of concentrations
tested (Figure 8A). Similar results were obtained for IL-6,
although the threshold concentration for the induction of IL-6
gene  expression  was  higher  than  that  required  for  VEGF
(0.3 mg/ml FDP-lysine-HSA; Figure 8B). FDP-lysine-HSA
also elevated TNF-α transcript levels, an effect that increased
to a maximum at 0.3 mg/ml and then became less pronounced
at higher concentrations (Figure 8C).
As determined by annexin V labeling, control cells and
those  treated  with  concentrations  of  FDP-lysine-HSA
≤0.3 mg/ml remained viable and were primarily Annexin V
and PI negative (Figure 9). A rightward shift in the FACS
profile, indicative of apoptosis, was observed for cells treated
with >0.4 mg/ml FDP-lysine-HSA (Figure 9).
DISCUSSION
To the best of our knowledge, this study is the first to address
the distribution pattern of ALEs in the diabetic retina. During
early experimental diabetes there is a selective accumulation
of the acrolein-derived ALE, FDP-lysine, in the Müller glia,
whereas  no  changes  were  detected  in  the  intensity  or
distribution  of  other  ALE  adducts,  including  4-HNE-
histidine,  4-HHE-histidine,  and  MDA-lysine.  The
accumulation of FDP-lysine begins after only a few months
of diabetes and is initially restricted to Müller glia end feet at
the ILM, but as the disease progresses this adduct appears in
Figure 7. Differential effects of Nε-(3-
formyl-3,4-dehydropiperidino)lysine
(FDP-lysine)  on  heme  oxygenase  1
(HO-1),  glial  fibrillary  acidic  protein
(GFAP), and Kir4.1 protein levels. A-
F:  Representative  western  blots  and
corresponding quantification for HO-1,
GFAP,  and  Kir4.1  protein  levels  in
control and FDP-lysine human serum
albumin  (HSA)-treated  human  Muller
(MIO-M1) cells. Incubation with FDP-
lysine-HSA  evoked  a  concentration-
dependent increase in HO-1, no change
in total GFAP levels, and a decrease in
Kir4.1  protein  expression  at  high
treatment concentrations (≥0.4 mg/ml).
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2533Figure 8. Nε-(3-formyl-3,4-dehydropiperidino)lysine (FDP-lysine)
accumulation  is  associated  with  changes  in  angiogenic  and
inflammatory  gene  expression.  Bar  graphs  showing  the
concentration-dependent  induction  of  (A)  vascular  endothelial
growth  factor  (VEGF),  (B)  interleukin-6  (IL-6),  and  (C)  tumor
necrosis factor-α (TNF-α) mRNAs following exposure of human
Muller (MIO-M1) cells to FDP-lysine human serum albumin (HSA).
mRNA levels were analyzed by real-time quantitative PCR using
gene-specific primers and normalized with β-actin as the internal
control.
the radial fibers extending toward the outer retina. Moreover,
our in vitro data clearly indicate that FDP-lysine is pathogenic
for retinal Müller glia.
Measurements of specific products of lipid peroxidation
have  revealed  that  concentrations  of  MDA  and  4-
hydroxyalkenals are increased in retinas from STZ-diabetic
rats  as  early  as  6  weeks  after  the  induction  of  diabetes
[41-43]. Higher lipid peroxide levels have also been reported
in retinas from human subjects with diabetes [44]. Despite
these previous findings, we found no evidence to suggest that
protein  modifications  by  MDA,  4-HNE,  or  4-HHE  are
significantly  increased  in  the  diabetic  rat  retina.  The
antibodies  used  in  the  current  study  have  been
comprehensively  tested  and  validated  in
immunohistochemistry-based studies [31,45,46], and thus it
seems unlikely that the apparent discrepancy in these results
can be attributed to the loss or masking of relevant ALE
epitopes. An alternative explanation could be that any increase
in  the  generation  of  these  adducts  may  be  effectively
compensated for by their rapid degradation via the ubiquitin–
proteasomal pathway. Some support for this possibility comes
from a previous study by Du et al. [47] who found that the
increased formation of oxidatively modified proteins in retinal
cells treated with high glucose was only detectable following
inhibition of proteosomal activity.
An obvious question that arises from this study is: “Why
do FDP-lysine adducts selectively accumulate in Müller glia
during diabetes”? Although further studies are clearly needed
to address this issue, some insights may be gleaned from the
existing  literature.  In  contrast  to  MDA  and  4-
hydroxyalkenals, ACR, the precursor of FDP-lysine, is not
only formed endogenously during lipid peroxidation but can
also be produced as a result of the oxidation of threonine by
the  myeloperoxidase  system  of  neutrophils  [48]  and  the
amine-oxidase-mediated  degradation  of  the  polyamines
spermine and spermidine [49]. One of the distinctive features
of Müller glia that could make them particularly susceptible
to ACR/FDP-lysine formation during diabetes is that these
cells constitute the main polyamine storage cells of the retina
[50].  As  such,  the  selective  accumulation  of  FDP-lysine-
modified proteins in these cells could potentially be accounted
for if polyamine catabolism were modified in the diabetic
retina. Although future work is needed in this area, it has been
reported that plasma amine oxidase activity is significantly
elevated in patients with type 1 and type 2 diabetes [51,52]
and  correlates  with  the  incidence  of  diabetic  retinopathy
[52]. While changes in polyamine catabolism could underlie
the diabetes-induced accumulation of FDP-lysine in Müller
glia, an alternative explanation could be that these adducts
originate from an exogenous rather than endogenous source.
Our in vitro data clearly demonstrate that Müller glia are
capable  of  internalizing  and  accumulating  FDP-lysine-
modified protein, and the observation that these adducts first
appear in the Müller glia end feet at the vitreoretinal interface
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2534indicates that the vitreous humor could represent a potential
source.
Previous studies have demonstrated increased levels of
FDP-lysine at sites of brain ischemia [53], in the retina of an
experimental  model  of  retinitis  pigmentosa  [54],  in  brain
tissue from Alzheimer disease patients [55], in atherosclerotic
lesions from human aorta [30], and in spinal cord following
traumatic injury [56]. It is perhaps surprising, therefore, that
no studies to date have examined the effects of FDP-lysine
accumulation on cellular function and survival in any cell
type. In the present study we have explored the role of FDP-
lysine on diabetic retinopathy-linked pathology. This adduct
causes  Müller  glia  dysfunction,  including  increased
expression of cytokines and dysregulated Kir4.1 expression.
This  may  be  directly  linked  to  oxidative  stress,  as
demonstrated  by  HO-1  induction  concomitant  with  FDP-
lysine-mediated loss of antioxidant defenses [39]. In addition,
previous  work  has  shown  that  ocular  inflammation  is
associated with a downregulation of inwardly rectifying K+
currents in Müller cells of the rat retina [57]. Thus, it is also
possible  that  the  downregulation  of  the  Kir4.1  channel
observed in the present study may, at least in part, be related
to the upregulation of inflammatory cytokines.
Diabetes  is  one  of  the  few  pathological  states  where
Müller cell apoptosis has been shown to occur [12]. Nuclear
translocation of glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) is thought to be a critical step in the diabetes-
induced  apoptosis  of  retinal  Müller  cells  [58],  and  this
mechanism  is  reported  to  play  a  significant  role  in  the
development and progression of diabetic retinopathy [59,60].
In the current study, exposure of MIO-M1 cells to a high
concentration  of  FDP-lysine-HSA  caused  extensive
apoptosis, suggesting that the observed accumulation of these
adducts  could  potentially  contribute  to  Müller  cell  death
during long-term diabetes. Interestingly, FDP-lysine binds to
and inactivates GAPDH [39], although whether this acts as
stimulus for the nuclear translocation of this protein remains
unknown. It would also be of interest to examine the effects
of FDP-lysine treatment on the regulation of IL-1β and the E3
ubiquitin ligase SIAH-1, both of which have been implicated
in the nuclear translocation and accumulation of GAPDH in
retinal Müller cells under hyperglycemic conditions [61,62].
Exposure of MIO-M1 to 0.5 mg/ml FDP-lysine-HSA not only
triggered widespread apoptosis but was also associated with
a  marked  increase  in  the  accumulation  of  FDP-lysine-
modified protein. This is most likely explained by the fact that
as apoptosis proceeds, the integrity of the plasma membrane
is disrupted and cells become increasingly permeable to large
macromolecules [63].
Figure  9.  Fluorescence-activated  cell
sorting (FACS) analysis of apoptosis in
human  Muller  (MIO-M1)  cells
incubated  with  Nε-(3-formyl-3,4-
dehydropiperidino)lysine  (FDP-lysine)
human serum albumin (HSA) measured
using  fluorescein  isothiocyanate
(FITC)-labeled  annexin  V  and  PI.  A:
Representative scatter plots showing the
distribution of annexin V and PI staining
for  control  and  FDP-lysine-HSA-
treated  MIO-M1  cells.  Cells  are
classified  as  “viable”  (bottom  left),
“apoptotic” (bottom right), or “necrotic”
(top left and right). Cells exposed to 0.5
mg/ml  FDP-lysine  HSA  showed  a
distinct  shift  into  the  bottom  right
quadrant, consistent with apoptosis (B).
Quantitative analysis of the percentage
of viable, apoptotic, or necrotic cells by
FACS  analysis.  ***  p<0.001  versus
untreated cells.
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2535In  conclusion  this  study  has  demonstrated  that  FDP-
lysine accumulates in Müller glia during diabetes and that this
adduct  could  be  linked  to  dysfunction  of  these  important
retinal cells. Over the last few years, several pharmacological
agents that display promising reactivity toward both ACR and
FDP-lysine  adducts  have  been  identified  [27].  Preclinical
testing of these compounds in appropriate animal models of
diabetes may provide a unique opportunity to begin to address
the role of Müller cell changes in the pathogenesis of diabetic
retinopathy.
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